Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Transplantation

Belatacept improves long-term outcomes in kidney transplantation

Kidney transplant patients treated with belatacept showed a 43% reduction in risk of death or graft loss.

Long-term outcomes better for patients who receive both more-intensive and less-intensive belatacept treatment after kidney transplant compared with ciclosporin treatment, new research shows. In the image, close-up of kidney after transplant

Source: Dr Barry Slaven / Visuals Unlimited, Inc / Science Photo Library

Patients who undergo kidney transplantation require prolonged immunosuppressive therapy to prevent rejection

Preventing rejection after kidney transplantation requires prolonged immunosuppressive therapy. Although this improves short-term outcomes it is not clear what the long-term impact is.

To understand more, researchers randomly assigned 660 kidney transplant patients to a more intensive or less intensive treatment with belatacept or a ciclosporine regimen and followed them for up to seven years. Patients treated with either belatacept regimen showed a 43% reduction in the risk of death or graft loss compared with ciclosporine treatment. The mean estimated glomerular filtration rate (eGFR) increased over the seven years in the patients treated with belatacept, and fell in the patients treated with ciclosporine.

Reporting in The New England Journal of Medicine[1] (online, 28 January 2016), the researchers note that the survival benefit emerged as early as five years after transplantation.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20200566

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Long-term outcomes were better for patients who received belatacept treatment after kidney transplant compared with ciclosporin treatment, new research shows. In the image, close-up of kidney after transplant

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.